Effect of Epigallocatechin Gallate supplementation on type 2 diabetes

Studing the effects of Epigallocatechin Gallate supplementation on lipid profile, Insulin resistance, Oxidative stress and inflammatory factors in rs9939609 FTO gene variants in type 2 diabetic patients.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017021612949N3

Enrollment

Registered

2017-04-04

Start date

2017-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: All patients will receive 300 mg (2×150mg) epigallocatechin Gallate capsules for 8 weeks. Intervention 2: All patients will receive 300 mg (2×150 mg) placebo capsules (Nokhodchi flour)

Treatment - Drugs

All patients will receive 300 mg (2×150mg) epigallocatechin Gallate capsules for 8 weeks.

All patients will receive 300 mg (2×150 mg) placebo capsules (Nokhodchi flour) for 8 weeks.

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Men or women aged between 20 to 60 years old, Minimum 2 years experience in diabete. Exclusion criteria: Alcohol consumption; smoking; Pregnant and lactating women; injection insulin; Taking anti inflammatory drugs; Using nutrition supplements; Hormone Therapy; Patients with a history of hypothyroidism; renal failure.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lipid profile (TG, LDL, HDL, Total cholestrol). Timepoint: Before and after 8 weeks intervention. Method of measurement: Mg/dl, laboratory kit.;Serum Total Anti Oxidant Capacity (TAOC). Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;High sensitive C reactive protein. Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;Interleukin 6. Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;Fasting Blood Sugar (FBS). Timepoint: Before and after 8 weeks intervention. Method of measurement: Mg/dl, laboratory kit.;Insulin. Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;Insulin Resistance (IR). Timepoint: Before and after 8 weeks intervention. Method of measurement: Based on HOMA IR equation.	—

Measure

Time frame

Lipid profile (TG, LDL, HDL, Total cholestrol). Timepoint: Before and after 8 weeks intervention. Method of measurement: Mg/dl, laboratory kit.;Serum Total Anti Oxidant Capacity (TAOC). Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;High sensitive C reactive protein. Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;Interleukin 6. Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;Fasting Blood Sugar (FBS). Timepoint: Before and after 8 weeks intervention. Method of measurement: Mg/dl, laboratory kit.;Insulin. Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;Insulin Resistance (IR). Timepoint: Before and after 8 weeks intervention. Method of measurement: Based on HOMA IR equation.

—

Secondary

Measure	Time frame
Body Mass Index (BMI). Timepoint: Before and after 8 weeks intervention. Method of measurement: Weight (kilograms) divided by the square of height (meters).;Sistolic and diastolic blood pressure. Timepoint: Before and after 8 weeks intervention. Method of measurement: By mercury sphygmomanometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMeysam Alipour

Ahvaz Jundishapur University of Medical Sciences

Alipour.m@ajums.ac.ir+98 61 3333 3050

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026